Neural antibodies can specifically label and recognize molecules on nerve cells, enabling a more comprehensive understanding and study of the biological properties, functions, and mechanisms of nerve cells in neurodegenerative diseases.
Covering iPSC neural cells, brain organoids, and microelectrode array services, our tools support neural development, disease modeling, and drug screening with high quality and reliable performance to meet diverse research needs.
Immobilized Cynomolgus ADAM9, His Tag (Cat. No. AD9-C52H7) at 1 μg/mL (100 μL/well) can bind Izeltabart with a linear range of 0.03-1 ng/mL (QC tested).
The purity of Rat ADAM9 Protein, His Tag (Cat. No. AD9-R52H4) is more than 90% and the molecular weight of this protein is around 50-75 kDa verified by SEC-MALS.
Synonym Name
Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-)Cellular disintegrin-related protein,Meltrin-gamma,Metalloprotease/disintegrin/cysteine-rich protein 9,Myeloma cell metalloproteinase,ADAM9,KIAA0021, MCMP, MDC9, MLTNG
Background
ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases.Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumoraggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers.Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.